Abbott India Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Abbott India Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $434.4K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Abbott India Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $434.4K Trade | TransData Nexus

Abbott India Limited

Indian Pharmaceutical Exporter · Brand Names & OTC Products Specialist · $434.4K Total Trade · DGFT Verified

Abbott India Limited is an Indian pharmaceutical exporter with a total trade value of $434.4K across 2 products in 2 therapeutic categories. Based on 94 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Brufen ($414.4K), Liraglutide ($20.0K), .

Abbott India Limited — Export Portfolio & Destination Treemap

Abbott India Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Abbott India Limited? — Company Overview & Market Position

Abbott India Limited, a subsidiary of Abbott Laboratories, has been a significant player in India's pharmaceutical sector for over a century. Established in 1910, the company has its headquarters in Mumbai, Maharashtra. As a publicly listed entity, Abbott India Limited is traded on the Bombay Stock Exchange under the ticker symbol 500488. The company operates under the Corporate Identification Number (CIN) L24239MH1944PLC004698. With a workforce exceeding 12,000 employees, Abbott India Limited offers a diverse portfolio encompassing established pharmaceuticals, nutritional products, medical devices, and diagnostic tests.

In the fiscal year ending March 31, 2023, Abbott India Limited reported a gross profit of approximately ₹1,000 crore, reflecting a consistent upward trajectory in its financial performance. The company's total equity for the same period stood at around ₹2,500 crore, indicating robust financial health and a solid foundation for future growth.

What Does Abbott India Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Brufen$414.4K 2

Product Portfolio — Top 2 by Export Value

Abbott India Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Brufen	Brand Names & OTC Products	$414.4K	89	9.2%	3
2	Liraglutide	Diabetes & Endocrine	$20.0K	5	0.5%	4

Abbott India Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $434.4K. The top category is Brand Names & OTC Products (95.4% of portfolio), followed by Diabetes & Endocrine (4.6%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Abbott India Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Abbott India Limited operates two state-of-the-art pharmaceutical manufacturing facilities located in Baddi, Himachal Pradesh, and Verna, Goa. These plants are designed to produce high-volume, quality formulations using cost-efficient processes. Equipped with well-equipped laboratories and trained personnel, they ensure compliance with international quality standards. The Goa plant, in particular, has been recognized for its commitment to environmental sustainability, achieving a zero-waste status.

3Key Leadership

As of March 2026, the Managing Director and CEO of Abbott India Limited is Munir Shaikh, who has been instrumental in steering the company's strategic direction and growth initiatives. The Chief Financial Officer (CFO) is not publicly disclosed in the available sources. The Board of Directors comprises experienced professionals overseeing various facets of the company's operations, ensuring adherence to corporate governance standards and driving the company's mission to enrich lives through quality healthcare solutions.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Abbott India Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Abbott India Limited has a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained regulatory approvals for several of its pharmaceutical products in these regions, facilitating market access and distribution. For instance, Abbott's nutritional products, such as Ensure and Glucerna, are available in multiple international markets, adhering to the respective regulatory standards. The company's commitment to quality and compliance has enabled it to establish a strong foothold in these markets, contributing to its global revenue streams.

2Emerging Markets

In emerging markets across Africa, Latin America, and Southeast Asia, Abbott India Limited has strategically positioned itself to address the growing healthcare needs. The company's products, including nutritional supplements and medical devices, are accessible in these regions, supported by WHO prequalification and adherence to local regulatory standards. This global outreach underscores Abbott India's commitment to providing quality healthcare solutions to diverse populations, enhancing its international market presence.

3Geographic Strategy

Abbott India Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Abbott India Limited's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA), ensuring compliance with stringent quality standards. The company has received approvals for several Abbreviated New Drug Applications (ANDAs), facilitating the export of generic pharmaceutical products to the U.S. market. Additionally, Abbott India has filed Drug Master Files (DMFs) with the FDA, providing detailed information about the manufacturing processes and quality controls of its products. The facilities have undergone FDA inspections, with no significant observations reported, reflecting the company's commitment to maintaining high-quality manufacturing practices.

2WHO & EU GMP

Abbott India Limited's manufacturing facilities hold certifications from the World Health Organization (WHO) and comply with European Union Good Manufacturing Practice (EU GMP) standards. These certifications affirm the company's adherence to international quality benchmarks, ensuring the safety and efficacy of its pharmaceutical products. The Goa plant, in particular, has been recognized for its commitment to environmental sustainability, achieving a zero-waste status.

3CDSCO & Indian Regulatory

Abbott India Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the Indian pharmaceutical market, Abbott India Limited faces competition from several key players, including Sun Pharmaceutical Industries, Cipla, and Dr. Reddy's Laboratories. While Abbott India holds a significant market share in certain therapeutic categories, it does not lead in any specific category. The company's portfolio concentration, with its top five products accounting for 100% of its exports, suggests a strategic focus on a select range of products. This concentration may expose the company to risks associated with market fluctuations in these specific product categories.

2Key Differentiators

Abbott India Limited's key differentiators include its extensive experience in the Indian market, a diverse product portfolio spanning various therapeutic areas, and a strong commitment to quality and compliance with international standards. The company's manufacturing facilities, recognized for their environmental sustainability efforts, further enhance its reputation. Additionally, Abbott India's strategic focus on both domestic and international markets allows it to leverage growth opportunities across different regions.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Abbott India Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Abbott India Limited has a strong track record in the pharmaceutical industry, with a consistent export volume and adherence to international quality standards. The company's manufacturing facilities are registered with the FDA and comply with WHO and EU GMP standards, indicating reliability and commitment to quality. The absence of significant regulatory observations or warnings further underscores the company's reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications when considering Abbott India Limited as a supplier:

FDA Registration: Confirm the company's manufacturing facilities are registered with the U.S. Food and Drug Administration.

WHO-GMP Certification: Ensure the manufacturing facilities comply with World Health Organization Good Manufacturing Practice standards.

EU GMP Certification: Verify adherence to European Union Good Manufacturing Practice standards.

Frequently Asked Questions — Abbott India Limited

How many pharmaceutical products does Abbott India Limited export from India?

Abbott India Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Brufen ($414.4K), Liraglutide ($20.0K). Total export value is $434.4K.

What is Abbott India Limited's total pharmaceutical export value?

Abbott India Limited's total pharmaceutical export value is $434.4K, based on 94 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Abbott India Limited cover?

Abbott India Limited exports across 2 therapeutic categories. The largest are Brand Names & OTC Products (95.4%, 1 products), Diabetes & Endocrine (4.6%, 1 products).

Get Full Abbott India Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.